will be conducted throughout the United States.

The application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested pesons may express their views in writing on the question whether consummation of the proposal can "reasonably be excepted to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices." Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Comments regarding the application must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than April 8, 1988.

A. **Federal Reserve Bank of New York** (William L. Rutledge, Vice President) 33 Liberty Street, New York, New York 10045:

1. *Midland Bank, PLC,* London, England; to engage *de novo* through its subsidiary, Thomas Cook, Inc., Princeton, New Jersey, in the purchase and sale of foreign currency as approved by Board order. *Southern Bancorporation Inc.,* 69 *Fed. Res. Bull.* 224 (1983).

Board of Governors of the Federal Reserve System, March 15, 1988.

**William W. Wiles,**

*Secretary of the Board.*

[FR Doc. 88-6058 Filed 3-18-88; 8:45 am]

BILLING CODE 6210-01-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Office of the Secretary

### Assistant Secretary for Management and Budget; Model Framework for Management Control Over Automated Information Systems, January 1988

**SUMMARY:** In a January 15, 1988 memorandum, M-88-10, the Deputy Director of the Office of Management and Budget, Joseph R. Wright issued an important document for managers and others working with automated information systems. The complete text of Mr. Wright's memorandum is repeated here:

Memorandum for the Heads of Departments and Agencies

From: Joseph R. Wright, Jr., Deputy Director

Subject: Model Framework for Management Control Over Automated Information Systems

I am pleased to provide you with the attached document entitled *Model Framework for Management Control Over Automated Information Systems.* This document is the product of a joint undertaking by the President's Council on Management Improvement and the President's Council on Integrity and Efficiency to help Federal managers better understand, establish, and document internal controls for their systems. I am initiating actions to institutionalize a program to facilitate the type of coordinated and integrated thinking provided in the document.

I believe the document can be useful guidance to Federal managers in better understanding certain requirements for control imposed by the Federal Manager's Financial Integrity Act of 1982, the Privacy Act of 1974, and OMB Circular Nos. A-123, A-127, and A-130. The document provides an integrated view of these requirements and adds nothing new. Thus, it will be an important tool for orienting Federal managers in the effective and responsible use of modern information technologies to support their programs.

The *Model Framework* was the product of many months of coordination across Federal agencies. It was clear from the 41 responses submitted on the February 1987 draft of the document from 27 agencies, that there is a need for this (or similar) methodology. Reviewers' comments provided the basis for the revision of the draft and recommendations for further work, which were presented to the President's Councils on Management and Improvement, and Integrity and Efficiency last fall.

The finalized *Model Framework* has been distributed to affected Committee Chairpersons and Members of the U.S. Senate and House of Representatives, Department and Agency Heads and Senior Information Resources Management (IRM) officials, and principals on the Interagency Committee on officials, and principals on the Interagency Committee on IRM sponsored by the General Services Administration.

#### Ordering Information

The document has been formally distributed to the Heads of Departments and Agencies, and single copies can be obtained from the contact identified below while supplies last. Additional copies of the document may be obtained by contacting the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402, (202) 783-3238. GPO Stock Number is 017-000-00255-4; unit price is $3.50.

**FOR FURTHER INFORMATION CONTACT:** Wallace O. Keene, Deputy Director, Office of Finance, HHS, 200 Independence Avenue SW., Room 737H, Washington, DC 20201. Telephone: (202) 245-7084.

Dated: March 15, 1988.

**S. Anthony McCann,**

*Assistant Secretary for Management and Budget.*

[FR Doc. 88-6123 Filed 3-18-88; 8:45 am]

BILLING CODE 4150-04-M

### Office of the Assistant Secretary for Health

### Advisory Council on Health Care Technology Assessment; Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), announcement is made of the following National Advisory Council scheduled to meet during the month of April 1988:

*Name:* National Advisory Council on Health Care Technology Assessment (Medicare Coverage Process Subcommittee).

*Date and Time:* April 19, 1988—8:30 a.m. to 4:00 p.m.

*Place:* Dupont Plaza Hotel, Embassy A Room, 1500 New Hampshire Avenue, Northwest, Washington, DC.

Open for entirety of meeting.

*Purpose:* The Council is charged to provide advice to the Secretary and to the Director of the National Center for Health Services Research and Health Care Technology Assessment (NCHSR) with respect to the performance of health care technology assessment functions prescribed by section 305 of the Public Health Service Act, as amended.

*Agenda:* The meeting will be devoted to discussions of a draft report of the findings, conclusions, and possible recommendations resulting from the Subcommittee's study of the technology assessment and Medicare coverage processes. The draft report will address timing of assessments, the internal HCFA review process, and the OHTA assessment process.

Anyone wishing to obtain a Roster of Members, Minutes of Meetings, or other relevant information should contact Mrs. Kelly Fennington, National Center for Health Services Research and Health Care Technology Assessment, Room 1805, Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857. Telephone (301) 443–5650.

Agenda items are subject to change as priorities dictate.

Date: March 11, 1988.

**J. Michael Fitzmaurice,**

*Director, National Center for Health Service Research and Health Care Technolgy Assessment.*

[FR Doc. 88–6066 Filed 3–18–88; 8:45 am]

BILLING CODE 4160–17–M

## Centers for Disease Control

### Project Grants for Preventive Health Services; Sexually Transmitted Diseases Control; Availability of Funds for Fiscal Year 1988

#### Introduction

The Centers for Disease Control (CDC) announces the availability of funds for Fiscal Year 1988 for Project Grants for Sexually Transmitted Diseases (STD) Control programs.

#### Authority

This grant program is authorized under the Public Health Service Act, Section 318 (42 U.S.C. 247c), as amended. Regulations governing programs for preventive health services are codified at 42 CFR Part 51b, Subparts A and D. The Catalog of Federal Domestic Assistance Number is 13.977.

#### Eligible Applicants

Eligible applicants are the official public health agencies of State and local governments, including the District of Columbia, American Samoa, the Commonwealth of Puerto Rico, the Virgin Islands, the Federated States of Micronesia, Guam, the Northern Mariana Islands, the Republic of Marshall Islands, and the Republic of Palau.

#### Purpose

The purpose of this grant program is to reduce morbidity and mortality from STD by preventing cases and complications.

#### Availability of Funds

Approximately $48,500,000 will be available to award up to 65 grants. The average award is expected to be $745,000, with individual awards ranging from $15,000 to $3,000,000. Depending on the availability of funds, grants are usually funded in 12 month budget periods in a 3 to 5 year project period. Continuation awards within the project period are made on the basis of satisfactory progress in meeting project objectives and on the availability of funds. No new grants are expected to be made in 1988 since current grantees are coordinating activities in all political jurisdictions in the United States. Funding estimates outlined above may vary and are subject to change.

#### Information

Applications are subject to review as governed by Executive Order 12372, Intergovernmental Review of Federal Programs. Application forms, information on review procedures, deadlines and the consequences of late submission, copies of the program announcement and regulations may be obtained from the appropriate Department of Health and Human Services Regional Office as set forth below.

Dated: March 14, 1988.

**Robert L. Foster,**

*Acting Director, Office of Program Support, Centers for Disease Control.*

#### Department of Health and Human Services (HHS) Regional Offices

Regional Health Administrator, PHS, HHS Region I, John Fitzerald Kennedy Building, Boston, Massachusetts 02203, (617) 223–6827

Regional Health Administrator, PHS, HHS Region II, Federal Building, 26 Federal Plaza, Room 3337, New York, New York 10278, (212) 264–2561

Regional Health Administrator, PHS, HHS Region III, Gateway Building #1, 3512–35 Market Street, Mailing Address: P.O. Box 12716, Philadelphia, Pennsylvania 19101, (215) 596–6637

Regional Health Administrator, PHS, HHS Region IV, 101 Marietta Tower, Suite 1007, Atlanta, Georgia 30323, (404) 221–2316

Regional Health Administrator, PHS, HHS Region V, 300 South Wacker Drive, 33rd Floor, Chicago, Illinois 60606, (312) 353–1385

Regional Health Administrator, PHS, HHS Region VI, 1200 Main Tower Building, Room 1835, Dallas, Texas 75202, (214) 767–3879

Regional Health Administrator, PHS, HHS Region VII, 601 East 12th Street, Kansas City, Missouri 64106, (816) 426–3291

Regional Health Administrator, PHS, HHS Region VIII, 1185 Federal Building, 1961 Stout Street, Denver, Colorado 80294, (303) 844–6163

Regional Health Administrator, PHS, HHS Region IX, 50 United Nations Plaza, San Francisco, California 94102, (415) 556–5810

Regional Health Administrator, PHS, HHS Region X, 2901 Third Avenue, M.S. 402, Seattle, Washington 98121, (206) 442–0430

[FR Doc. 88–6069 Filed 3–18–88; 8:45 am]

BILLING CODE 4160–18–M

## Food and Drug Administration

[Docket No. 88F–0054]

### Shell Oil Co.; Filing of Food Additive Petition

**AGENCY:** Food and Drug Administration.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that the Shell Oil Co. has filed a petition proposing that the food additive regulations be amended to permit the use of hydrogen peroxide solution to sterilize food-contact surfaces prepared from poly-1-butene resins and butene/ethylene copolymers.

**FOR FURTHER INFORMATION CONTACT:** Edward J. Machuga, Center for Food Safety and Applied Nutrition (HFF–335), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–472–5690.

**SUPPLEMENTARY INFORMATION:** Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786 (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 8B4062) has been filed by Shell Oil Co., Houston, TX 77210, proposing that § 178.1005 *Hydrogen peroxide solution* (21 CFR 178.1005) be amended to provide for the safe use of hydrogen peroxide solution to sterilize food-contact surfaces prepared from poly-1-butene resisns and butene/ethylene copolymers complying with § 177.1570.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: March 14, 1988.

**Fred R. Shank,**

*Acting Director, Center for Food Safety and Applied Nutrition.*

[FR Doc. 88–6061 Filed 3–18–88; 8:45 am]

BILLING CODE 4160–01–M

**Advisory Committees; Meetings; Blood Products Advisory Committee; et al.**

**AGENCY:** Food and Drug Administration.

**ACTION:** Notice.

**SUMMARY:** This notice announces forthcoming meetings of public advisory committees of the Food and Drug Administration (FDA). This notice also summarizes the procedures for the meetings and methods by which interested persons participate in open public hearings before FDA's advisory committees.

Meetings: The following advisory committee meetings are announced:

**Blood Products Advisory Committee**

*Date, time, and places.* April 7 and 8, 1988, 8:30 a.m., April 7, 1988, Wilson Hall, 3rd Floor, Bldg. 1; and April 8, 1988, Jack Masur Auditorium, Warren Grant Magnuson Clinical Center, Bldg. 10, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD.

*Type of meeting and contact person.* Open public hearing, April 7, 1988, 8:30 a.m. to 9:30 a.m., unless public participation does not last that long; open committee discussion, 9:30 a.m. to 11 a.m.; closed presentation of data, 11 a.m. to 11:30 a.m.; closed committee deliberations, 11:30 a.m. to 12:30 p.m.; open committee discussion, 1:30 p.m. to 3 p.m.; closed committee deliberations, 3 p.m. to 5:30 p.m.; open committee discussion, April 8, 1988, 8 a.m. to 5 p.m.; Linda Smallwood, Division of Blood and Blood Products (HFB–830), Office of Biologics Evaluation and Research, Food and Drug Administration, 8800 Rockville Pike Bethedsa, MD 20892, 301–497–0393

*General function of the committee.* The committee reviews and evaluates available data on the safety effectiveness, and appropriate use of blood products intended for use in the diagnosis, prevention, or treatment of human disease.

*Agenda—Open public hearing.* Interested persons requesting to present data, information, or views, orally or in writing, on issues pending before the committed should communicate with the committee contact person.

*Open committee discussion.* On the morning of April 17, 1988, the committee will discuss a medical device premarket approval application for a test for hepatitis B core antibody (DuPont), and in the afternoon will hear an update on human immunodeficiency virus (HIV) testing issues. On April 8, 1988, the committeee will participate in the Public Workshop on "the Application of Biosafety Principles in Blood Establishments".

*Closed presentation of data.* The committee will discuss trade secret or confidential commercial information relevant to the DuPont medical device premarket approval application for the anti-hepatitis B core antigen test. This portion of the meeting will be closed to permit discussion of this information (5 U.S.C. 552b(c)(4)).

*Closed committee deliberations.* The committee will discuss trade secret or confidential commercial information relevant to the pending medical device premarket application, investigational new biological product applications, and biological product license applications. This portion of the meeting will be closed to permit discussion of this information (5 U.S.C. 552(b)(c)(4)).

**Science Advisory Board to the National Center for Toxicological Research**

*Date, time, and place.* April 7 and 8, 1988, 9 a.m., Bldg. 13, Conference Room, National Center for Toxicological Research, Jefferson, AR.

*Type of meeting and contact person.* Open committee discussion, April 7, 1988, 9 a.m. to 5 p.m.; open committee discussion, April 8, 1988, 9 a.m. to 10 a.m.; closed committee discussion, 10 a.m. to 12:30 p.m. and 2 p.m. to 3 p.m.; Ronald F. Coene, National Center for Toxicological Research, Food and Drug Administration, 5600 Fishers Lane, Rm. 14–101, Rockville, MD 20857, 301–443–3155.

*General function of the board.* The board advises the Director, National Center for Toxicological Research (NCTR), in establishing and implementing a research program that will assist the Commissioner of Food and Drugs in fulfilling his regulatory responsibilities. The board provides that extra-agency review in ensuring that research programs at NCRT are scientifically sound and pertinent to its stated goals and objectives.

*Agenda—Open public hearing.* Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make a formal presentation should notify the board contact person before April 1, 1988, and submit a brief statement of the general nature of the evidence or argument they wish to present, the name and address of proposed participants, and an indication of the approximate time requested to make their comments.

*Open board discussion.* The board will receive an update of NCTR's progress on the "Project on Caloric Restriction." A final agenda will be available on March 29, 1988, by communicating with the board contact person.

*Closed board deliberations.* The board will review the projects and progress of NCTR's post-doctoral fellowship programs. This portion of the meeting will be closed to prevent disclosure of personal information concerning individuals associated with these programs, disclosure of which would constitute a clearly unwarranted invasion of personal privacy (5 U.S.C. 552b(c)(6)).

**Ophthalmic Devices Panel**

*Date, time, and place.* April 21 and 22, 1988, 9 a.m., Auditorium Hubert H. Humphrey Bldg., 200 Independence Ave., SW., Washington, DC.

*Type of meeting and contact person.* Open public hearing April 21, 1988, 9 a.m. to 10 a.m.; open committee discussion, 10 a.m. to 3 p.m.; closed committee deliberations, 3 p.m. to 4 p.m.; open committee discussion, 4 p.m. to 5 p.m.; open public hearing, April 22, 1988, 9 a.m. to 10 a.m.; open committee discussion, 10 a.m. to 3 p.m.; closed committee deliberations, 3 p.m. to 4 p.m.; open committee discussion, 4 p.m. to 5 p.m.; Dr. Daniel W. C. Brown, Center for Devices and Radiological Health (HFZ–460), Food and Drug Administration, 8757 Georgia Ave., Silver Spring, MD 20910, 301–427–7320.

*General function of committee.* The committee reviews and evaluates available data on the safety and effectiveness of devices currently in use and makes recommendations for their regulation. The committee also reviews data on new devices and makes recommendations regarding their safety, effectiveness, and suitability for marketing.

*Agenda—Open public hearing.* Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact persons before April 2, 1988, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.

*Open committee discussion.* On April 21, 1988, the committee will discuss general issues relating to approvals of premarket approval applications (PMA's) for Nd:YAG lasers and intraocular lenses (IOL's), and may discuss specific PMA's for these devices. It discussion of all pertinent Nd:YAG laser or IOL issues is not completed, discussion will be continued the following day. On April 22, 1988, the committee will discuss PMA's for

contact lenses and other devices, and requirements for PMA approval.

*Closed committee deliberation.* On April 21, and 22, 1988, the committee may discuss trade secret and/or confidential commercial or financial information relevent to PMA's for IOL's Nd:YAG lasers, contact lenses, or other ophthalmic devices. These portions of the meeting will be closed to permit discussion of this information (5 U.S.C. 552b(c)(4)).

**Circulatory System Devices Panel**

*Date, time, and place.* April 29, 1988, 8:30 a.m., Rm. 703–727A, Hubert H. Humphrey Bldg., 200 Independence Ave. SW., Washington, DC.

*Type of meeting and contact person.* Open public hearing, 8:30 a.m. to 9:30 a.m.; open committee discussion, 9:30 a.m. to 2:30 p.m.; closed committee deliberations, 2:30 p.m. to 4 p.m.; Dr. Keith Lusted, Center for Devices and Radiological Health (HFZ–450), Food and Drug Administration, 8757 Georgia Ave., Silver Spring, MD 20910, 301–427–7594.

*General function of the committee.* The committee reviews and evaluates available data on the safety and effectiveness of medical devices currently in use and makes recommendations for their regulation.

*Agenda—Open public hearing.* Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before April 15, 1988, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.

*Open committee discussion.* The committee will discuss a premarket approval application (PMA) for a prosthetic heart valve and have a discussion of Panel evaluation of PTCA (percutaneous transluminal coronary angioplasty) catheters.

*Closed committee deliberations.* The committee will discuss trade secret and/or confidential commercial or financial information regarding the PMA's listed above. This portion of the meeting will be closed to permit discussion of this information (5 U.S.C. 552b(c)(4)).

Each public advisory committee meeting listed above may have as many as four separable portions: (1) An open public hearing, (2) an open committee discussion, (3) a closed presentation of data, and (4) a closed committee deliberation. Every advisory committee meeting shall have an open public hearing portion. Whether or not it also includes any of the other three portions will depend upon the specific meeting involved. The dates and times reserved for the separate portions of each committee meeting are limited above.

The open public hearing portion of each meeting shall be at least 1 hour long unless public participation does not last that long. It is emphasized, however, that the 1 hour time limit for an open public hearing represents a minimum rather than a maximum time for public participation, and an open public hearing may last for whatever longer period the committee chairperson determines will facilitate the committee's work.

Public hearings are subject to FDA's guideline (Subpart C of 21 CFR Part 10) concerning the policy and procedures for electronic media coverage of FDA's public administrative proceedings, including hearings before public advisory committees under 21 CFR Part 14. Under 21 CFR 10.205, representatives of the electronic media may be permitted, subject to certain limitations, to videotape, film, or otherwise record FDA's public administrative proceedings, including presentations by participants.

Meetings of advisory committees shall be conducted, insofar as is practical, in accordance with the agenda published in this **Federal Register** notice. Changes in the agenda will be announced at the beginning of the open portion of a meeting.

Any interested person who wishes to be assured of the right to make an oral presentation at the open public hearing portion of a meeting shall inform the contact person listed above, either orally or in writing, prior to the meeting. Any person attending the hearing who does not in advance of the meeting request an opportunity to speak will be allowed to make an oral presentation at the hearing's conclusion, if time permits, at the chairperson's discretion.

Persons interested in specific agenda items to be discussed in open session may ascertain from the contract person the approximate time of discussion.

Details on the agenda, questions to be addressed by the committee, and a current list of committee members are available from the contact person before and after the meeting. Transcripts of the open portion of the meeting will be available from the Freedom of Information Office (HFI–35), Food and Drug Administration, Rm. 12A–16, 5600 Fishers Lane, Rockville, MD 20857, approximately 15 working days after the meeting, at a cost of 10 cents per page. The transcript may be viewed at the Dockets Management Branch (HFA–305), Food and Drug Administration, Rm. 4–62, 5600 Fishers Laine, Rockville, MD 20857, aproximately 15 working days after the meeting, between the hours of 9 a.m. and 4 p.m., Monday through Friday. Summary minutes of the open portion of the meeting will be available from the Freedom of Information Office (address above) beginning approximately 90 days after the meeting.

The Commissioner, with the concurrence of the Chief Counsel, has determined for the reasons stated that those portions of the advisory committee meetings so designated in this notice shall be closed. The Federal Advisory Committee Act (FACA), as amended by the Government in the Sunshine Act (Pub. L. 94–409), permit such closed advisory committee meetings in certain circumstances. Those portions of a meeting designated as closed, however, shall be closed for the shortest possible time, consistent with the intent of the cited statutes.

The FACA, as amended, provides that a portion of a meeting may be closed where the matter for discussion involves a trade secret; commercial or financial information that is privileged or confidential; information of a personal nature, disclosure of which would be a clearly unwarranted invasion of personal privacy; investigatory files compiled for law enforcement purposes; information the premature disclosure of which would be likely to significantly frustrate implementation of a proposed agency action; and information in certain other instances not generally relevant to FDA matters.

Examples of portions of FDA advisory committee meetings that ordinarily may be closed, where necessary and in accordance with FACA criteria, include the review, discussion, and evaluation of drafts of regulations or guidelines or similar preexisting internal agency documents, but only if their premature disclosure is likely to significantly frustrate implementation of proposed agency action; review of trade secrets and confidential commercial or financial information submitted to the agency; consideration of matters involving investigatory files complied for law enforcement purposes; and review of matters, such as personnel records or individual patient records, where disclosure would constitute a clearly unwarranted invasion of personal privacy.

Examples of portions of FDA advisory committee meetings that ordinarily shall not be closed include the review, discussion, and evaluation of general preclinical and clinical test protocols and procedures for a class of drugs or

devices; consideration of labeling requirements for a class of marketed drugs or devices; review of data and information on specific investigational or marketed drugs and devices that have previously been made public; presentation of any other data or information that is not exempt from public disclosure pursuant to the FACA, as amended; and, notably deliberative sessions to formulate advice and recommendations to the agency on matters that do not independently justify closing.

This notice is issued under section 10(a)(1) and (2) of the Federal Advisory Committee Act (Pub. L. 92–463, 86 Stat. 770–776 (5 U.S.C. App. I)), and FDA's regulations (21 CFR Part 14) on advisory commitee.

Dated: March 15, 1988.

**Frank E. Young,**

*Commissioner of Food and Drugs.*

[FR Doc. 88–6060 Filed 3–18–88; 8:45 am]

BILLING CODE 4160–01–M

## Advisory Committee Meetings; Veterinary Medicine Advisory Committee et al.

**AGENCY:** Food and Drug Administration.

**ACTION:** Notice.

**SUMMARY:** This notice announces forthcoming meetings of public advisory committees of the Food and Drug Administration (FDA). This notice also summarizes the procedures for the meetings and methods by which interested persons may participate in open public hearings before FDA's advisory committees.

**MEETINGS:** The following advisory committee meetings are announced:

### Veterinary Medicine Advisory Committee

*Date, time, and place.* April 12 and 13, 1988, 8:15 a.m., Conference Rm. I, Parklawn Bldg., 5600 Fishers Lane, Rockville, MD.

*Type of meeting and contact person.* Open committee discussion, April 12, 1988, 8:15 a.m. to 8:45 a.m.; open public hearing, 8:45 a.m. to 9:45 a.m., unless public participation does not last that long; open committee discussion, 9:45 a.m. to 4:30 p.m.; open committee discussion, April 13, 1988, 8 a.m. to 8:15 a.m.; open public hearing, 8:15 a.m. to 8:45 a.m.; open committee discussion, 8:45 a.m. to 11:30 a.m.; Max Crandall, Center for Veterinary Medicine (HFV–4), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–3450.

*General function of the committee.* The committee reviews and evaluates available data on the safety and effectiveness of marketed and investigational new animal drugs, feeds, and devices for use in the treatment and prevention of animal diseases and increased animal production.

*Agenda—Open public hearing.* Interested persons requesting to present data, information, or views, orally or in writing, on issues pending before the committee should communicate with the committee contact person.

*Open committee discussion.* The committee will discuss: (1) Criteria for classification of prescription and over-the-counter products, (2) sulfamethazine residues, and (3) CVM new research programs.

### Oncologic Drugs Advisory Committee

*Date, time, and place.* April 19, 1988, 8:30 a.m., Parklawn Bldg., Conference Rms. G and H, 5600 Fishers Lane, Rockville, MD.

*Type of meeting and contact person.* Open committee discussion, 8:30 a.m. to 4 p.m.; open public hearing, 4 p.m. to 5 p.m., unless public participation does not last that long; David F. Hersey, Center for Drug Evaluation and Research, Rm. 8B–45, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–4695.

*General function of the committee.* The committee reviews and evaluates available data on the safety and effectiveness of marketed and investigational human drugs for use in the treatment of cancer.

*Agenda—Open public hearing.* Interested persons requesting to present data, information, or views, orally or in writing, on issues pending before the committee should comunicate with the committee contact person.

*Open committee discussion.* The committee will discuss: (1) Ifosfamide (NDA 19763) for use in combination with approved cytotoxic drugs for treatment of refractory testicular cancer; (2) FDA requirements for approval of new drugs for treatment of colon cancer and rectal cancer; (3) treatment of advanced metastatic colorectal cancer; (4) leucovorin and fluorouracil for advanced metastatic colon cancer; and (5) adjuvant therapy of rectal cancer.

### Dermatologic Drugs Advisory Committee

*Date, time, and place.* April 26, 1988, 8:30 a.m., Conference Rms. D and E, Parklawn Bldg., 5600 Fishers Lane, Rockville, MD.

*Type of meeting and contact person.* Open public hearing, 8:30 a.m. to 9:30 a.m., unless public participation does not last that long; open committee discussion, 9:30 a.m. to 4:30 p.m.; Thomas E. Nightingale, Center for Drug Evaluation and Research, Rm. 8B–45, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–4695.

*General function of the committee.* The committee reviews and evaluates available data on the safety and effectiveness of marketed and investigational human drugs for use in dermatologic disorders.

*Agenda—Open public hearing.* Interested persons requesting to present data, information, or views, orally or in writing, on issues pending before the committee should communicate with the committee contact person.

*Open committee discussion.* The committee will discuss: (1) Adverse effects of isotretinoin (Accutane/ Hoffmann-LaRoche, Inc.); and (2) an update on evaluation patch test kits.

### Pulmonary-Allergy Drugs Advisory Committee

*Date, time, and place.* April 28 and 29, 1988, 8:30 a.m., Conference Rm. 10, 6th floor, Bldg. 31, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD.

*Type of meeting and contact person.* Open public hearing, April 28, 1988, 8:30 a.m. to 9:30 a.m., unless public participation does not last that long; open committee discussion, 9:30 a.m. to 5 p.m.; open committee discussion, April 29, 1988, 8:30 a.m. to 2:30 p.m.; Isaac F. Roubein, Center for Drug Evaluation and Research, Rm. 8B–45, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–4695.

*General function of the committee.* The committee reviews and evaluates available data on the safety and effectiveness of marketed and investigational human drugs for use in the treatment of pulmonary disease and diseases with allergenic and/or immunologic mechanisms.

*Agenda—Open public hearing.* Interested persons requesting to present data, information, or views, orally or in writing, on issues pending before the committee should communicate with the committee contact person.

*Open committee discussion.* On April 28, 1988, the committee will discuss: (1) The new drug evaluation review process, (2) the use of caffeine for apnea of prematurity, and (3) data supporting pediatric use of inhaled albuterol. On April 29, the committee will discuss the guidelines for testing bronchodilators.

FDA public advisory committee meetings may have as many as four separable portions: (1) An open public hearing, (2) an open committee discussion, (3) a closed presentation of

data, and (4) a closed committee deliberation. Every advisory committee meeting shall have an open public hearing portion. Whether or not it also includes any of the other three portions will depend upon the specific meeting involved. There are no closed portions for the meetings announced in this notice. The dates and times reserved for the open portions of each committee meeting are listed above.

The open public hearing portion of each meeting shall be at least 1 hour long unless public participation does not last that long. It is emphasized, however, that the 1 hour time limit for an open public hearing represents a minimum rather than a maximum time for public participation, and an open public hearing may last for whatever longer period the committee chairperson determines will facilitate the committee's work.

Public hearings are subject to FDA's guideline (Subpart C of 21 CFR Part 10) concerning the policy and procedures for electronic media coverage of FDA's public administrative proceedings, including hearings before public advisory committees under 21 CFR Part 14. Under 21 CFR 10.205, representatives of the electronic media may be permitted, subject to certain limitations, to videotape, film, or otherwise record FDA's public administrative proceedings, including presentations by participants.

Meetings of advisory committees shall be conducted, insofar as is practical, in accordance with the agenda published in this **Federal Register** notice. Changes in the agenda will be announced at the beginning of the open portion of a meeting.

Any interested person who wishes to be assured of the right to make an oral presentation at the open public hearing portion of a meeting shall inform the contact person listed above, either orally or in writing, prior to the meeting. Any person attending the hearing who does not in advance of the meeting request an opportunity to speak will be allowed to make an oral presentation at the hearing's conclusion, if time permits, at the chairperson's discretion.

Persons interested in specific agenda items to be discussed in open session may ascertain from the contact person the approximate time of discussion.

Details on the agenda, questions to be addressed by the committee, and a current list of committee members are available from the contact person before and after the meeting. Transcripts of the open portion of the meeting will be available from the Freedom of Information Office (HFI-35), Food and Drug Administration, Rm. 12A-16, 5600 Fishers Lane, Rockville, MD 20857, approximately 15 working days after the meeting, at a cost of 10 cents per page. The transcript may be viewed at the Dockets Management Branch (HFA-305), Food and Drug Administration, Rm. 4-62, 5600 Fishers Lane, Rockville, MD 20857, approximately 15 working days after the meeting, between the hours of 9 a.m. and 4 p.m., Monday through Friday. Summary minutes of the open portion of the meeting will be available from the Freedom of Information Office (address above) beginning approximately 90 days after the meeting.

This notice is issued under section 10(a)(1) and (2) of the Federal Advisory Committee Act (Pub. L. 92-463, 86 Stat. 770-776 (5 U.S.C. App. I)), and FDA's regulations (21 CFR Part 14) on advisory committees.

Dated: March 14, 1988.

**Adam J. Trujillo,**

*Acting Commissioner for Regulatory Affairs.*

[FR Doc. 88-6059 Filed 3-18-88; 8:45 am]

BILLING CODE 4160-01-M

## Health Resources and Services Administration

### Public Health Service, Final Funding Priority for Grants for Programs for Physician Assistants

The Health Resources and Services Administration announces the final funding priority which will be applied in the distribution of grant awards in Fiscal Year 1988 for Grants for Programs for Physician Assistants.

Section 783(a) authorizes the award of grants to accredited schools of medicine or osteopathy and other public or nonprofit private entities to assist in meeting the cost of planning, developing and operating or maintaining programs for the training of physician assistants as defined under section 701(8) of the Public Health Service Act.

To receive support, programs must meet the requirements of sections 701(8) and 783(a) of the Act and program regulations implementing these sections published at 42 CFR Part 57, Subparts H and I.

In determining the priority for funding of applications recommended for approval, consideration will be given to the following factors:

1. The extent to which the applicant develops and uses methods designed to attract, maintain and graduate minority and disadvantaged students;

2. Conducting substantial portions of the programs in a health manpower shortage area(s) or in an area health education center, funded under section 781 of the PHS Act;

3. Establishment of a program in a State which does not have a program; and

4. Conducting a program in conjunction with primary care physician education in a manner which shares educational resources and encourages the use of physician assistants by physicians.

In addition, a proposed funding priority was published in the **Federal Register** of January 5, 1988 (53 FR 184) for public comment. No comments were received during the 30-day comment period.

Therefore, as proposed, a funding priority will be given to projects which expand or develop and implement new curriculum concerning the prevention of HIV-infection and the care of HIV-infected persons, including AIDS patients.

Physician Assistants are increasingly required to provide a wide range of services to HIV-infected persons, including AIDS patients, in both inpatient and outpatient settings. However, organized formal curricular offerings for these trainees are not in place. This priority is designed to encourage new offerings.

This program is listed at 13.886 in the *Catalog of Federal Domestic Assistance.* Applications submitted in response to this announcement are not subject to the provisions of Executive Order 12372 Intergovernmental Review of Federal Programs, (as implemented through 45 CFR Part 100).

Dated: March 15, 1988.

**David N. Sundwall,**

*Administrator, Assistant Surgeon General.*

[FR Doc. 88-6110 Filed 3-18-88; 8:45 am]

BILLING CODE 4160-15-M

## National Institutes of Health

### National Cancer Institute; Cancer Biology-Immunology Contract Review Committee; Meeting

Pursuant to Pub. L. 92-463, notice is hereby given of the meeting of the Cancer Biology-Immunology Contract Review Committee, National Cancer Institute, National Institutes of Health, April 25, 1988, 9000 Rockville Pike, Building 31C, Conference Room 8, Bethesda, Maryland 20892.

This meeting will be open to the public on April 25 from 9 a.m. to 9:30 a.m. to discuss administrative details. Attendance by the public will be limited to space available.

In accordance with provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. and sec. 10(d) of Pub. L.